COMBINATION THERAPY FOR OVARIAN CANCER
The present invention provides a method to treat ovarian cancer by the administration of effective amounts of picoplatin and doxorubicin.
1 . A method of treating ovarian cancer, comprising:
co-administering to a human patient afflicted with ovarian cancer, picoplatin and DL (doxorubicin hydrochloride or liposomal doxorubicin), wherein the picoplatin is administered prior to the DL, at least once at a dosage of about 60-150 mg/m 2 and the DL is administered at least once at a dosage of about 20-60 mg/m 2 .
2 . The method of claim 1 wherein the dosage of the picoplatin is administered at about 120 mg/m 2 and the dosage of the DL is subsequently administered at about 30-75 mg/m 2 .
3 . The method of claim 1 or 2 wherein the picoplatin is administered followed up to about 2 days later by administration of the DL.
4 . The method of claim 3 wherein the picoplatin and the DL are both administered intravenously or intraperitoneally.
5 . The method of claim 3 wherein the picoplatin is administered followed after about 10 minutes to about one hour later by administration of the DL.
6 . The method of claim 4 wherein the picoplatin and the DL are each administered over about a one hour period.
7 . The method of claim 3 wherein the picoplatin and the DL are both administered about once every 3 to about 6 weeks.
8 . The method of claim 7 wherein the picoplatin and the DL are both administered about every 4 weeks.
9 . The method of claim 7 wherein the picoplatin and the DL are each administered at least twice.
10 . The method of claim 7 wherein the picoplatin and the DL are each administered for about 2 to about 10 treatments.
11 . The method of claim 1 wherein the picoplatin is administered at doses of about 110-120 mg/m 2 .
12 . The method of claim 3 wherein the level of CA-125 cancer antigen of the patient is decreased relative to the level of CA-125 cancer antigen of a comparable patient not receiving the treatment.
13 . The method of claim 3 wherein an effective anti-emetic amount of a 5-HT 3 receptor antagonist and dexamethasone are administered to the patient prior to administration of the picoplatin or the DL.
14 . The method of claim 3 wherein the dosage of picoplatin reduces or eliminates at least one of the side effects associated with the DL.
15 . The method of claim 14 wherein the side effect is Hand-Foot syndrome.
16 . The method of claim 14 wherein the DL reduces or eliminates at least one of the side effects associated with the picoplatin.
17 . The method of claim 15 wherein the side effect is myelotoxicity.
18 . The method of claim 3 wherein the ovarian cancer is refractory to treatment by cisplatin or carboplatin.
19 . The method of claim 3 wherein the ovarian cancer is resistant to treatment by cisplatin or carboplatin.